These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 24465710)
1. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. Gou HF; Huang J; Shi HS; Chen XC; Wang YS PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710 [TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer. Gou HF; Zhou L; Huang J; Chen XC Mol Med Rep; 2018 Aug; 18(2):2335-2341. PubMed ID: 29956798 [TBL] [Abstract][Full Text] [Related]
3. Immunogenic death of colon cancer cells treated with oxaliplatin. Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547 [TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model. Golchin S; Alimohammadi R; Rostami Nejad M; Jalali SA J Cell Physiol; 2019 Nov; 234(11):19866-19874. PubMed ID: 30941773 [TBL] [Abstract][Full Text] [Related]
5. Targeted co-delivery of rapamycin and oxaliplatin by liposomes suppresses tumor growth and metastasis of colorectal cancer. Yu H; Liu S; Yuan Z; Huang H; Yan P; Zhu W Biomed Pharmacother; 2024 Sep; 178():117192. PubMed ID: 39098178 [TBL] [Abstract][Full Text] [Related]
6. An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer. Wang Q; Wang Z; Wu Y; Klinke DJ BMC Cancer; 2020 Jan; 20(1):26. PubMed ID: 31914948 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130 [TBL] [Abstract][Full Text] [Related]
8. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039 [TBL] [Abstract][Full Text] [Related]
9. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. Correale P; Rotundo MS; Del Vecchio MT; Remondo C; Migali C; Ginanneschi C; Tsang KY; Licchetta A; Mannucci S; Loiacono L; Tassone P; Francini G; Tagliaferri P J Immunother; 2010 May; 33(4):435-41. PubMed ID: 20386463 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. Correale P; Cusi MG; Del Vecchio MT; Aquino A; Prete SP; Tsang KY; Micheli L; Nencini C; La Placa M; Montagnani F; Terrosi C; Caraglia M; Formica V; Giorgi G; Bonmassar E; Francini G J Immunol; 2005 Jul; 175(2):820-8. PubMed ID: 16002679 [TBL] [Abstract][Full Text] [Related]
11. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. Cross-Knorr S; Lu S; Perez K; Guevara S; Brilliant K; Pisano C; Quesenberry PJ; Resnick MB; Chatterjee D BMC Cancer; 2013 Oct; 13():463. PubMed ID: 24098947 [TBL] [Abstract][Full Text] [Related]
12. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model. Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870 [TBL] [Abstract][Full Text] [Related]
13. Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models. Göschl S; Schreiber-Brynzak E; Pichler V; Cseh K; Heffeter P; Jungwirth U; Jakupec MA; Berger W; Keppler BK Metallomics; 2017 Mar; 9(3):309-322. PubMed ID: 28205649 [TBL] [Abstract][Full Text] [Related]
14. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394 [TBL] [Abstract][Full Text] [Related]
15. Immunogenic chemotherapy in two mouse colon cancer models. Taniura T; Iida Y; Kotani H; Ishitobi K; Tajima Y; Harada M Cancer Sci; 2020 Oct; 111(10):3527-3539. PubMed ID: 32816355 [TBL] [Abstract][Full Text] [Related]
16. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Guo J; Yu Z; Sun D; Zou Y; Liu Y; Huang L Mol Cancer; 2021 Jan; 20(1):10. PubMed ID: 33407548 [TBL] [Abstract][Full Text] [Related]
17. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354 [TBL] [Abstract][Full Text] [Related]
18. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
20. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo]. Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]